Did you know vision loss has the highest direct health costs of any disease category in Canada? Taking into account lower employment rates, decreased earning potential, depression, and premature death, annual costs of vision loss in Canada could rise to an estimated $30.3 billion by 2032.
That’s why it’s so important to champion the development and delivery of safe and effective treatments and cures for vision loss in Canada. On this page, you’ll find information about our work to bring new treatments and cures to Canadians, and opportunities to support our efforts.
Share your vision story
Living with a blinding eye disease can feel isolating. Hearing others’ vision loss experiences can help provide hope. That’s why FBC is asking you to share your vision story with our community.
Your vision story can be shared in a variety of ways:
- On the FBC website
- At an FBC event
- In a peer-to-peer meeting opportunity
- Through the FBC Ambassador Program
Sharing your experience of living with vision loss can help to underscore the importance of vision research – and provide hope to those at different points in their vision loss journey.
LEARN ABOUT FBC Policy work and Publications
Vision 2020 White papers
The year 2020 is symbolic for those living with vision loss, and is a reminder that more needs to be done to address the complex issues that affect this growing community. Fighting Blindness Canada (FBC), the Canadian Council of the Blind (CCB), CNIB Foundation, and other stakeholders have collaborated to draft three papers that discuss living with vision loss, vision research, and access to vision care.
Regulatory Submission Highlights
FBC provides patient input to government agencies to ensure that they are considering the vision loss community’s lived experience as they are making decisions about regulations, budgets or providing recommendations about which treatments should be approved and funded.
- Inherited Retinal Diseases (IRDs) Submission | Treatment: voretigene neparvovec (Luxturna®) | Agency: Canadian Association for Drugs and Technologies in Health (CADTH) | Submitted May 21, 2020
- Age-related Macular Degeneration (AMD) Submission | Treatment: brolucizumab (Beovu®) | Agency: Canadian Association for Drugs and Technologies in Health (CADTH) | Submitted October 18, 2019
- Glaucoma Submission | Treatment: minimally invasive glaucoma surgery | Agency: Canadian Association for Drugs and Technologies in Health (CADTH) | Submitted September 21, 2018
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.